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Objectives This study was designed to investigate whether single nucleotide polymorphisms (SNPs) and haplotypes of the
fibrinogen gene-cluster (fibrinogen chains alpha [FGA], beta [FGB], and gamma [FGG]) could explain the inter-
and intraindividual variability of fibrinogen levels in patients with atherosclerosis. We also searched for genetic
determinants affecting the responses of fibrinogen genes to proinflammatory stimulation.
Background The mechanisms regulating fibrinogen levels are not fully understood, and they are likely to be regulated by
complex gene–environment interactions.
Methods In the AIRGENE study, 895 survivors of myocardial infarction from 5 European cities were followed prospectively
for 6 to 8 months, and plasma fibrinogen, interleukin (IL)-6, and C-reactive protein levels were determined
monthly. We analyzed 21 SNPs and the corresponding haplotypes in the 3 fibrinogen genes.
Results Eight SNPs in FGA and FGB were significantly associated with fibrinogen levels. Similarly, 2 different haplotypes in
FGA and 3 in FGB were also associated with mean fibrinogen levels. The IL-6 levels had a significant impact on the
associations between SNPs/haplotypes in FGA/FGB and fibrinogen levels. We also identified SNPs and haplotypes in
FGA and FGB with strong impact on the intraindividual variability of fibrinogen during the follow-up period.
Conclusions We identified common SNPs and haplotypes on FGA/FGB genes, explaining the interindividual and intraindi-
vidual variability of fibrinogen levels, in patients with a history of myocardial infarction. We have also identified
for the first time, SNPs/haplotypes on FGA/FGB whose effects on fibrinogen expression are modified by the un-
derlying IL-6 levels. These findings may have an impact on risk stratification and the design of genetically guided
therapeutic approaches in patients with advanced atherosclerosis. (J Am Coll Cardiol 2008;52:941–52)
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Haplotypes on Fibrinogen Genes in MI Survivors September 9, 2008:941–52Local and systemic low-grade
inflammation represent a key
feature in atherogenesis, and
increased plasma levels of in-
flammatory biomarkers such as
fibrinogen have been associated
with increased cardiovascular risk
(1). Further to its role as a non-
specific marker of inflammation,
fibrinogen may also have a direct
role in atherogenesis and throm-
bogenesis by acting as a bridging
molecule for many types of cell-
cell adhesion events critical for
atherogenesis (2). In addition, it
seems to be chemotactic for
mooth muscle cells (3) and to affect the stability of
theromatous plaque (4). Fibrinogen plays a central role in
he coagulation cascade with a critical impact on the
ormation of fibrin clots following the rupture of an athero-
clerotic plaque (5).
Plasma fibrinogen appears to have high variability in the
eneral population, because in addition to its seasonal
ariations (6), its expression is affected by the presence of
ild inflammatory stimuli induced by smoking (7), aging or
evere atherosclerosis (1). However, increasing evidence
uggests that 50% of the total variability in fibrinogen
evels is determined by genetic factors (8). Several single
ucleotide polymorphisms (SNPs) have been identified in
he genes encoding the 3 fibrinogen chains alpha, beta, and
amma (FGA, FGB, and FGG genes, respectively). Be-
ause the synthesis of the beta chain is rate-limiting for
brinogen’s synthesis in vitro (9), recent research has fo-
used mainly on the genetic variability of FGB. Some SNPs
n FGB have been associated with variation in plasma
brinogen levels (10,11). Although sequences responsive to
nterleukin (IL)-6 (which is the main mediator of acute
hase-induced fibrinogen synthesis) are present in the
romoter regions of the genes encoding all 3 fibrinogen
hains, recent evidence suggests that SNPs on the beta
hain have a major regulatory function in fibrinogen syn-
hesis in response to IL-6 (12). This genetically determined
ensitivity of fibrinogen expression to IL-6 may also explain
revious reports that specific SNPs on fibrinogen genes
ffect plasma fibrinogen levels only in subgroups with higher
L-6 levels such as smokers (13), or in subjects with an
nhanced acute phase response as determined by high
-reactive protein (CRP) levels (14).
In the present study, we hypothesized that SNPs and
aplotypes of the fibrinogen genes FGA, FGB, and FGG
ay affect mean plasma fibrinogen levels in patients with a
istory of myocardial infarction (MI). We also examined
hether these SNPs and the haplotypes defined by them
odify the complex relationship between fibrinogen, IL-6,
Abbreviations
and Acronyms
CRP  C-reactive protein
FGA  fibrinogen chain
alpha
FGB  fibrinogen chain
beta
FGG  fibrinogen chain
gamma
IL  interleukin
LD  linkage disequilibrium
MI  myocardial infarction
SNP  single nucleotide
polymorphismnd CRP in this population. bethods
tudy population and protocol. From a total cohort of
,003 patients with a history of MI participating in the
IRGENE study (15), 895 had suitable blood samples for
he present study. The patients were recruited from 5
uropean cities: Augsburg (Germany), Barcelona (Spain),
elsinki (Finland), Rome (Italy), and Stockholm (Sweden).
etails of the design of the study are given elsewhere (15).
ubjects were recruited through hospital- (Helsinki, Rome)
r population-based registries of patients with MI (Augs-
urg, Barcelona, Stockholm). The inclusion criteria were
urvival after MI 3 months to 6 years before entry into the
tudy and age between 35 and 80 years. Because of the rapid
hanges in the medical management of MI survivors during
he last few years, the limit of 6 years after MI was used to
ncrease study group homogeneity. Exclusion criteria were
I or interventional coronary procedure (percutaneous
ransluminal coronary angioplasty, coronary artery bypass
raft) less than 3 months before the beginning of the study;
esidence outside the defined study area; an extended period
f absence from the study area planned during the study
eriod; a major illness that would prevent compliance with
he study protocol; and chronic inflammatory diseases
nd/or anti-inflammatory medication (that might modify
he biomarkers considered in the study). Further, samples
rom visits where the patient indicated having had an
nfection, surgery, or a major dental intervention in the 3
ays before the visit were excluded and subsequently sub-
ects with 2 remaining valid blood samples were com-
letely excluded from the study. Other cardiovascular mor-
idities, such as heart failure, were not exclusion criteria.
The fieldwork consisted of a baseline visit, where an
xtensive questionnaire to characterize the patient was
dministered; blood pressure was measured, the body mass
ndex determined, a 12-lead resting electrocardiogram was
ecorded; and a venous blood sample was drawn to measure
lood count, total cholesterol, high density lipoprotein
holesterol and glycosylated hemoglobin HbA1c, and in-
ammatory markers (fibrinogen, IL-6, and CRP) and to
xtract deoxyribonucleic acid. Patients were followed up
rospectively for an average of 6 monthly visits. At each
onthly visit, the inflammatory markers were measured and
short questionnaire was completed to characterize the 24 h
revious to the visit in terms of time spent in traffic, amount
f exercise, tea and alcohol consumption, smoking, and
xposure to environmental tobacco smoke, to detect an
cute infection and to record changes in medication.
iochemical measurements. Blood samples were stored at
°C until centrifugation. The resulting plasma samples were
tored at 80°C until shipped to the central laboratory in
lm, Germany, where high-sensitivity CRP and fibrinogen
ere analyzed by immunonephelometry on a BNII analyzer
Dade Behring Marburg GmbH, Marburg, Germany, for
oth CRP and fibrinogen). For IL-6, a high-sensitivity
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September 9, 2008:941–52 Haplotypes on Fibrinogen Genes in MI Survivorsolorimetric sandwich enzyme-linked immunoadsorbent as-
ay (R&D Systems GmbH, Abingdon, United Kingdom)
as used. For quality control, 102 fibrinogen duplicates
ere obtained; the mean of the coefficients of variation in
he duplicates was 6.1% (from 2.5% in Augsburg to 11.2%
n Rome). The interassay coefficient of variation was 3.6% at
.35 g/l.
enotyping. Out of a total of 134 SNPs genotyped for the
IRGENE study, 27 SNPs located in the genes FGA,
GB, and FGG were investigated for the present study. We
elected all up-to-then known haplotype tagging SNPs,
ossibly functional SNPs, as well as DNA variants showing
n association in other studies with cardiovascular disease or
elated phenotypes. For SNP selection, the National Centre
or Biotechnology SNP database dbSNP Build 124, based
n NCBI Human Genome Build 35.1 (16), the Innate
mmunity Program for Genomic Applications database
17), and the SeattleSNPs Program for Genomic Applica-
ions (18) were used.
Genotyping was carried out by using the MassARRAY
ystem (Sequenom, San Diego, California) (19). All reac-
ions (PCR amplification, base extension) were carried out
n a Tetrad PCR thermal cycler (MJ Research, St. Bruno,
uebec).
Eleven SNPs were genotyped in FGA, 8 in FGB, and 8
n FGG. For 2 SNPs (1 in FGB and 1 in FGG), no assay
ould be established or the assay did not provide valid
esults. Two SNPs (1 in FGA and 1 in FGG) were
onomorphic in the study population and 2 (both in FGA)
ad a minor allele frequency below 1%. Finally, 21 fibrinogen
ene SNPs were taken into the statistical analyses (rs2070022,
s6050, rs2070018, rs2070016, rs2070014, rs2070011,
s10012555, and rs2070006 in FGA; rs1800791, rs1800790,
s1800788, rs2227399, rs6056, rs4220, and rs2227421 in
GB; and rs2066865, rs1049636, rs2066861, rs2066860,
s1800792, and rs2066854 in FGG). The average success rate
or these 21 SNPs in the 3 genes was 93%.
For quality control, sex determination was performed for
ll samples by amplification of a partial sequence of the
melogenin gene (AMELX) and thus validated genotyping
ssays. No samples had to be excluded for this analysis.
Negative controls were included on all genotyping plates.
or 30% of samples randomly selected and genotyped in
uplicate, the replication rate was 99.82%. Each SNP was
ested for departures from Hardy-Weinberg equilibrium by
eans of a chi-square test or Fisher exact test depending on
llele frequency. None of the SNPs in the 3 selected genes
eviated significantly from Hardy-Weinberg equilibrium.
stimation of haplotypes. The genewise regions appropri-
te for haplotype estimation and haplotype association
nalysis were identified through linkage disequilibrium
LD) analysis. Haplotype blocks were defined as regions
ith Lewontin’s D' 0.8 between consecutive SNPs. Only
ndividuals with complete SNP information were included
n the haplotype estimation. To reduce the number of fiubjects with missing genotypes, highly correlated SNPs
ere used to impute missing values. In each group of highly
orrelated SNPs (r20.95), missing values in the SNP with
he highest call rate were imputed from SNPs with lower
all rates, which subsequently were excluded from further
nalysis. In FGA, rs2070022 was complemented using
nformation from rs2070014. In FGB, rs6056 was filled up
sing rs4220, and missing values in rs2227399 were im-
uted based on rs1800790. For FGG, a group of 3 highly
orrelated SNPs was identified (rs2066861, rs2066865,
s2066854) with rs2066861 having the highest call rate. The
pdated versions of the SNPs rs6056, rs2227399, and
s2066861 entered haplotype estimation, but the 5 SNPs
hat were used for imputing missing values had to be
xcluded.
Haplotype estimation was performed for each gene using
he expectation-maximization algorithm presented by
chaid et al. (20) with SNPs entered in gene-specific
eading direction. To avoid bias resulting from genetic
ariation between populations, haplotypes were estimated
or each center separately. Analysis of individually estimated
aplotypes identified only 1 individual with a most probable
aplotype pair in gene FGG having a probability of 0.74.
ll other estimated most probable haplotype pairs in all 3
enes exceeded a probability of 0.94, with an overall
mbiguity rate of 8.9%. Additional information obtained
hrough alternative haplotype pairs, therefore, was assumed
o be small and only the individually most probable pair of
aplotypes was modeled in association analysis.
tatistical analysis. Statistical analysis was performed in 3
teps. In the first step, we identified the nongenetic variables
ssociated with fibrinogen levels; then we identified the
NPs associated with the fibrinogen levels; and finally we
reated a final model including the SNPs and the variables
hat fulfilled the confounder definition. This procedure was
rst done using all the centers and then city by city.
ovariates were selected from a list of potential confounders
s those found to change the estimated SNP effect by more
han 10%. Time invariant (from the baseline questionnaire)
s well as time variant (from the short questionnaire)
ariables with potential effects on fibrinogen levels were
ntered into the model one by one based on the criterion of
howing the minimum Akaike information criterion value.
inal adjustment was made for city, gender, age, body mass
ndex, HbA1c, and smoothed trend.
Power calculations suggested that the study sample was
ble to detect a 16% difference in fibrinogen levels between
enotypes, at a genotype frequency of 15% and alpha 0.05
ith a power of 80%.
As the outcome variable, we used the logarithm of the
easured fibrinogen values to normalize its distribution.
his implies that effects estimated can be expressed as
ercentage change of the geometric mean in the plasma
brinogen levels.
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Haplotypes on Fibrinogen Genes in MI Survivors September 9, 2008:941–52We used mixed effects models with random patient
ntercepts to account for the serial correlation among
epeated measurements within the framework of additive
ixed models to allow for nonparametric exposure-response
unctions (21).
Besides the 21 fibrinogen SNPs, we also tested 6 IL-6
nd 8 CRP SNPs. For each SNP, we both calculated the
ffect only adjusting for city and applied the confounder
odel to obtain an adjusted effect on the plasma fibrinogen
evel. For association analyses between the different SNPs
nd the fibrinogen levels, the original significance level of
lpha  0.05 was corrected for multiple testing following
he Sidak method. The number of tests was calculated as the
ffective number of independent loci among the SNPs
nalyzed according to Li and Ji (22). Finally, we constructed
mutually adjusted model with SNPs associated to fibrin-
gen levels in the univariate analysis. In the multiple
djusted model, we included one by one based on the
riterion of lowest Akaike information criterion, the SNPs
howing a significant association in the previous models;
urthermore, we excluded any SNP(s) having a high LD
r2 0.8) with the last SNP introduced in the model to
void collinearity. The common homozygote genotype of
ach SNP was used as reference. The same confounder
odel was used to estimate the association between haplo-
ypes and fibrinogen levels. As SNP analyses indicate a
enerally present additive effect, an additive effect is as-
umed in haplotype association analysis. Therefore, haplo-
ypes were coded as count variables with the most frequent
aplotype of each gene as reference.
For haplotype association analysis, only haplotypes with
stimated frequency of at least 0.05 in any center were coded
s single variables. All other haplotypes were pooled in a
roup of rare haplotypes unless this group turned out to be
ignificant. It turned out to be the case for a rare haplotype
n FGB gene, and we extracted the most frequent haplotype
rom this group for separate analysis.
We also investigated interactions between the significant
NPs of the fibrinogen genes and IL-6 or CRP levels in
ffecting fibrinogen levels. We tested interactions using
ontinuous IL-6 and CRP, and we stratified them by
uartiles to obtain the estimations. The same procedure was
ollowed for interactions with haplotypes. Finally, we ana-
yzed the intraindividual variability in fibrinogen levels
elated to each SNP by using the intraindividual standard
eviations of our repeated measurements of the logarithmi-
ally transformed fibrinogen in each individual as the
utcome variable, adjusting for individual mean logarithmi-
ally transformed fibrinogen and the final set of confounder
ariables described earlier.
esults
emographic characteristics and fibrinogen levels. The
emographic characteristics of the participants are pre- 3ented in Table 1. To minimize the variability of fibrinogen
evels, we performed serial measurements for each patient,
cross a period of 6 to 8 months (the average number of
onthly visits per subject for the participating centers was
pproximately 6 except in Barcelona where it was around 7).
he median fibrinogen level in the overall study population
as 3.5 g/l; however, there was a significant difference in
brinogen levels between patients from different geograph-
cal areas (lowest in Rome [median: 3.0 g/l] and highest in
arcelona [median: 4.1 g/l]). City of residence was the
trongest predictor of fibrinogen levels in our population,
espite the fact that 99.7% of the study participants were
aucasians.
enotype analysis. Analysis of LD for the 21 SNPs in the
haracteristics of the Study Population*
Table 1 Characteristics of the Study Population*
Number of participants, n
All cities 895
Augsburg 200
Barcelona 169
Helsinki 195
Rome 134
Stockholm 197
Number of visits, mean [range]
All cities 6.2 [2–8]
Augsburg 5.9 [2–7]
Barcelona 7.0 [2–8]
Helsinki 6.0 [2–6]
Rome 5.9 [2–8]
Stockholm 6.0 [2–8]
Male gender, n (%) 694 (77.5)
Diabetes, n (%)† 175 (19.6)
Respiratory disease, n (%)†‡ 101 (11.3)
Family history of MI, n (%) 129 (14.4)
Hypertension, n (%)† 452 (50.5)
Heart failure, n (%) 98 (11.0)
Ever smokers, n (%)§ 603 (67.4)
Age (yrs) 63.1 9.0
Body mass index (kg/m2) 28.3 4.2
Smoking (pack-yrs) 18.6 23.7
Glycosylated hemoglobin (%) 5.4 1.0
Serum cholesterol (mg/dl) 183.3 39.0
Alcohol intake per day (g) 14.4 19.9
Systolic blood pressure (mm Hg) 134.1 21.5
Inflammatory markers (median [range] in 5,327 person-visits)
Fibrinogen (g/l) 3.49 [3.0–4.1]
C-reactive protein (mg/l) 1.27 [0.7–2.8]
Interleukin-6 (pg/ml) 2.23 [1.6–3.3]
Hour of visit¶ 12 [7–19]
Trend# 240 [1–423]
Values are expressed as mean  standard deviation, unless stated otherwise. †Self-reported
hrough the baseline questionnaire and defined as ever diagnosed by a physician. ‡Includes
sthma, chronic bronchitis, and emphysema. §Includes ex-smokers, occasional smokers, and
ctive smokers. Includes treatment. ¶Hour of visit makes reference to the hour of the day when
he blood was withdrawn. #Trend makes reference to the number of days elapsed between the
ate of the first visit of the full study (May 19, 2003, in Augsburg) and the date of the corresponding
isit for any subject in any city.
MI  myocardial infarction.fibrinogen genes (FGA, FGB, and FGG on chromosome
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September 9, 2008:941–52 Haplotypes on Fibrinogen Genes in MI Survivors) indicated that for each gene all SNPs are in 1 haplotype
lock (Fig. 1). In addition, high correlation (r2 0.8) was
bserved for 3 separate pairs of SNPs in FGA, a group of 6
NPs in FGB, and a group of 3 SNPs in FGG. The
requencies of these SNPs and the respective haplotypes in
he study population are presented in Tables 2 and 3,
espectively. The allele frequencies and genotype distribu-
ion were similar to those found in a general population
rom Augsburg (data not shown).
There was no significant effect of any of the examined
NPs and haplotypes on baseline clinical status, as evaluated
y the presence of angina pectoris, arrhythmias, or heart
ailure (p  NS for all associations after taking into account
he p value adjusted for multiple comparisons).
ssociations between SNPs and fibrinogen levels. Eight
NPs (out of 21 included in the study) were significantly
ssociated with plasma fibrinogen levels in the analyses that
ncluded 1 SNP at a time (Table 2): 1) for FGA: rs2070011,
s2070006, rs2070022, rs2070014; and 2) for FGB:
s1800790, rs2227399, rs6056, rs4220.
Four of these SNPs held the calculated significance level
orrected for multiple testing (alpha 0.0026): 1) for FGA:
s2070011; and 2) for FGB: rs1800790, rs2227399, rs6056.
wo SNPs (FGA rs2070011 and FGB rs1800790s) re-
ained in the mutually adjusted model. FGB rs1800790s
xplained 1.9% of the variability in the fibrinogen concen-
ration and FGA rs2070011 explained 1.2%, in the crude
ivariate model. When both SNPs were included in the
ame model, 3.4% of the variability in the fibrinogen
oncentration was explained by the genetic variants, and
1.37% of the variability was explained by the nongenetic
Figure 1 LD Maps for FGA, FGB, and FGG
Linkage disequilibrium (LD) maps for the 3 fibrinogen chain genes: fibrinogen chai
are shown.ovariates. SNone of the tested SNPs in the FGG, IL-6, or CRP
enes showed a significant association with fibrinogen levels
data not shown).
ssociations between haplotypes and fibrinogen levels. We
ound that 1 haplotype of the FGA gene, TTTAACG
defined by the minor allele in rs6050 as described in Table
), showed significant association with fibrinogen levels. In
ddition, interestingly, 1 haplotype of FGA (CTCGATG),
efined by SNP rs2070016, was also associated with fibrin-
gen levels, although this SNP was not significantly asso-
iated in the SNP analyses.
We also observed that 3 haplotypes in the FGB gene were
ssociated with plasma fibrinogen levels. Two were defined
nly by SNPs associated with fibrinogen levels (Table 2):
CGTA was the only haplotype with the minor allele in
s6056, and GCGCA was defined by the allelic combina-
ion in both SNPs (rs2227399 and rs6056). The third
aplotype (GTTCA) associated with fibrinogen levels was
ainly defined by 1 SNP not associated with fibrinogen
evels in single SNP analyses (rs1800788). The distinction
etween this haplotype and the rare variant ATTCA
frequency 0.1%) can be made in rs1800791.
None of the haplotypes in the FGG gene showed a
ignificant association with fibrinogen levels as in the SNPs
nalyses.
ffect of SNPs and haplotypes on the response to
ow-grade inflammation. Individual means of plasma fi-
rinogen levels in the overall population were significantly
orrelated with both IL-6 (r  0.40, 95% confidence
nterval [CI]: 0.38 to 0.42) and CRP mean levels (r  0.53,
5% CI: 0.51 to 0.55). To test whether the examined
(FGA), beta (FGB), and gamma (FGG). D’ (red) and r2 (blue) measures of LDn alphaNPs/haplotypes modify the response of fibrinogen genes
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Table 2 Association Between SNPs in the FGA and FGB Genes and Plasma Fibrinogen Levels
Frequency, %
Crude (Adjusted Only for City) Adjusted for Identified Confounders*
% Change (95% CI) p Value % Change (95% CI) p Value
fgb_rs1800790
AA 4.0 13.5 (5.83 to 21.81) 0.0004 11.5 (4.44 to 19.10) 0.0010
GA 31.9 3.5 (0.67 to 6.37) 0.0149 3.8 (1.23 to 6.46) 0.0040
GG 64.1 0 (ref.) 0.0003 0 (ref.) <0.0001
fgb_rs2227399
GG 4.1 12.7 (4.87 to 21.05) 0.0011 10.8 (3.60 to 18.44) 0.0030
GT 32.2 3.6 (0.79 to 6.50) 0.0117 3.9 (1.34 to 6.56) 0.0030
TT 63.7 0 (ref.) 0.0005 0 (ref.) <0.0001
fgb_rs6056
TT 3.0 13.6 (4.83 to 23.13) 0.0019 10.8 (2.98 to 19.32) 0.0060
CT 30.6 3.1 (0.28 to 6.05) 0.0311 3.6 (0.96 to 6.27) 0.0070
CC 66.4 0 (ref.) 0.0015 0 (ref.) 0.0010
fgb_rs4220
AA 2.9 13.0 (4.04 to 22.75) 0.0038 10.8 (2.73 to 19.49) 0.0080
GA 30.7 3.2 (0.38 to 6.15) 0.0262 3.6 (1.00 to 6.31) 0.0070
GG 66.4 0 (ref.) 0.0023 0 (ref.) 0.0010
fga_rs2070011
TT 15.9 5.3 (1.35 to 9.31) 0.0080 5.9 (2.23 to 9.60) 0.0010
CT 46.2 0.3 (2.44 to 3.14) 0.8274 0.4 (2.16 to 2.94) 0.7820
CC 37.9 0 (ref.) 0.0194 0 (ref.) 0.0030
fga_rs2070006
TT 15.7 4.6 (0.77 to 8.63) 0.0184 5.4 (1.83 to 9.12) 0.0030
CT 47.2 0.3 (2.43 to 3.18) 0.8162 0.4 (2.12 to 3.01) 0.7530
CC 37.1 0 (ref.) 0.0451 0 (ref.) 0.0070
fga_rs2070022
AA 3.2 4.9 (11.36 to 2.09) 0.1660 6.0 (11.88 to 0.22) 0.0590
GA 28.0 3.7 (6.40 to0.85) 0.0111 3.7 (6.24 to1.19) 0.0040
GG 68.8 0 (ref.) 0.0221 0 (ref.) 0.0050
fga_rs2070014
TT 3.2 4.8 (11.33 to 2.13) 0.1693 6.0 (11.86 to 0.25) 0.0600
CT 27.3 3.6 (6.31 to0.74) 0.0137 3.7 (6.20 to1.13) 0.0050
CC 69.6 0 (ref.) 0.0266 0 (ref.) 0.0060
fga_rs2070016
GG 2.0 12.3 (2.58 to 23.04) 0.0121 8.7 (0.06 to 18.16) 0.0485
AG 25.6 0.5 (2.36 to 3.53) 0.7192 1.7 (0.97 to 4.50) 0.2113
AA 72.4 0 (ref.) 0.0424 0 (ref.) 0.0777
fgg_rs2066860
TT 0.1 11.4 (37.25 to 25.24) 0.4944 5.2 (30.76 to 29.75) 0.7382
CT 7.1 2.2 (6.79 to 2.57) 0.3571 3.0 (7.17 to 1.32) 0.1701
CC 92.7 0 (ref.) 0.5225 0 (ref.) 0.3713
fgg_rs2066854
AA 6.3 5.2 (0.15 to 10.89) 0.0568 6.0 (0.93 to 11.23) 0.0196
AT 36.6 1.2 (1.50 to 4.02) 0.3835 1.4 (1.11 to 3.95) 0.2788
TT 57.1 0 (ref.) 0.1444 0 (ref.) 0.0539
fgb_rs1800791
AA 2.8 3.6 (10.78 to 4.05) 0.3430 4.2 (10.66 to 2.74) 0.2295
GA 25.5 3.4 (6.23 to0.53) 0.0206 4.1 (6.61 to1.46) 0.0025
GG 71.7 0 (ref.) 0.0534 0 (ref.) 0.0069
fgb_rs2227421
CC 9.0 1.6 (6.14 to 3.06) 0.4860 2.2 (6.33 to 2.01) 0.2963
AC 45.2 1.8 (4.45 to 0.85) 0.1788 1.5 (3.89 to 0.98) 0.2354
AA 45.9 0 (ref.) 0.3886 0 (ref.) 0.3846Continued on next page
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lasma levels of IL-6 and CRP had any impact on the
elationship between SNPs and fibrinogen levels (Table 4).
ndeed, there was a significant interaction between IL-6
evels and the association of rs2070011 in FGA with
brinogen levels and a borderline interaction between CRP
evels and the association of the same SNP with fibrinogen
evels. Interestingly, the haplotype effect patterns of all 3
brinogen genes showed significant heterogeneity across
uartiles of IL-6 levels, indicating effect modification at the
aplotype level. The IL-6 levels appeared particularly to
ignificantly modify the association between fibrinogen
evels and 1 haplotype of FGA, 2 haplotypes of FGB (1
ignificantly and 1 borderline), and 2 haplotypes of FGG
both borderline) (Table 5), none of which showed signif-
ontinued
Table 2 Continued
Frequency, %
Crude (Adjus
% Change (95% CI
fgg_rs2066861
TT 6.1 4.9 (0.54 to 10.5
CT 36.4 1.2 (1.51 to 4.02
CC 57.6 0 (ref.)
fgg_rs2066865
AA 6.2 4.8 (0.61 to 10.4
GA 36.4 1.1 (1.67 to 3.85
GG 57.4 0 (ref.)
fga_rs6050
CC 7.7 3.5 (1.42 to 8.59
TC 37.3 2.1 (0.64 to 4.92
TT 55.0 0 (ref.)
fgb_rs1800788
TT 5.2 3.8 (2.05 to 9.92
CT 32.6 0.0 (2.78 to 2.77
CC 62.2 0 (ref.)
fga_rs2070018
GG 2.1 1.8 (6.75 to 11.1
AG 21.1 1.3 (1.85 to 4.45
AA 76.8 0 (ref.)
fga_rs10012555
CC 1.8 2.2 (6.62 to 11.9
TC 21.6 1.1 (1.99 to 4.33
TT 76.6 0 (ref.)
fgg_rs1049636
GG 9.9 2.9 (7.10 to 1.54
AG 41.4 2.0 (4.61 to 0.66
AA 48.7 0 (ref.)
fgg_rs1800792
CC 20.3 0.5 (3.09 to 4.21
TC 48.6 0.4 (3.28 to 2.57
TT 31.2 0 (ref.)
f the 21 tested single nucleotide polymorphisms (SNPs) in fibrinogen chains alpha (FGA), beta (FG
ny SNP), are shown. % change: percentage of change of fibrinogen geometric mean from the re
he italic p value in the reference row refers to the overall p value for both genotypes of the respe
f alpha  0.0026 for multiple comparisons. *Adjusted for city, gender, age, body mass index, gl
CI  confidence interval.cant overall association with fibrinogen levels (Table 3). Offect of SNPs and haplotypes on intraindividual vari-
bility of plasma fibrinogen. As fibrinogen levels appear to
ave high intraindividual variability across time, we then
xamined whether any of the examined SNPs and haplo-
ypes have an effect on this intraindividual variability of
lasma fibrinogen, in serial measurements from the same
ubjects across a 6- to 8-month period. The homozygote
A variant of SNP rs2227421 in the FGB gene was
ositively associated with the intraindividual standard devi-
tion of logarithmically transformed fibrinogen levels (co-
fficient: 0.015, 95% CI: 0.002 to 0.029), and the SNP
s2070006 in FGA showed a borderline negative associ-
tion, for both variants (heterozygote: coefficient:
0.008, 95% CI: 0.016 to 0.001; rare homozygote
ariant GG: coefficient:0.023, 95% CI:0.049 to 0.003).
ly for City) Adjusted for Identified Confounders*
p Value % Change (95% CI) p Value
0.0789 5.9 (0.81 to 11.21) 0.0225
0.3847 1.4 (1.08 to 3.98) 0.2679
0.1860 0 (ref.) 0.0589
0.0831 5.8 (0.76 to 11.15) 0.0238
0.4529 1.3 (1.22 to 3.83) 0.3188
0.2048 0 (ref.) 0.0662
0.1670 4.5 (0.07 to 9.27) 0.0538
0.1342 2.0 (0.48 to 4.61) 0.1132
0.1850 0 (ref.) 0.0779
0.2092 5.5 (0.09 to 11.29) 0.0462
0.9763 0.3 (2.83 to 2.24) 0.7993
0.4396 0 (ref.) 0.1134
0.6877 0.7 (8.39 to 7.59) 0.8598
0.4326 2.1 (0.73 to 5.09) 0.1458
0.6928 0 (ref.) 0.3328
0.6323 0.9 (8.83 to 7.62) 0.8224
0.4838 2.1 (0.79 to 5.06) 0.1562
0.7143 0 (ref.) 0.3462
0.1983 4.2 (7.98 to0.19) 0.0402
0.1390 1.4 (3.78 to 1.09) 0.2720
0.2214 0 (ref.) 0.1054
0.7896 0.3 (2.95 to 3.75) 0.8388
0.7897 0.1 (2.58 to 2.81) 0.9551
0.8694 0 (ref.) 0.9783
gamma (FGG), only the 8 with an Akaike information criterion lower than the null model (without
category. The p value is given for each genotype relative to the common homozygote reference.
P. Bold p values remain statistically significant when considering the corrected significance level
ted hemoglobin HbA1c (%), and smoothed trend.ted On
)
4)
)
8)
)
)
)
)
)
7)
)
4)
)
)
)
)
)
B), and
ference
ctive SNne FGA haplotype, CTCGATG (which was associated
Aa
%
[
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Table 3 Association Between FGA, FGB, and FGG Haplotypes and Plasma Fibrinogen Levels*
Haplotype
Frequency (%)
% Change (95% CI) of
Fibrinogen Levels Versus Reference p Value
FGA†
CTCAATG 29.3 0 (ref.) 0.001
TTTAACG 25.8 2.9 (0.7 to 5.0) 0.008
CTCAATA 17.0 1.7 (4.1 to 0.7) 0.168
CTCGATG 14.5 3.3 (0.7 to 6.0) 0.014
TCTAGTG 12.1 2.5 (0.2 to 5.2) 0.068
Rare 3.0 (4.0 to 10.4) 0.418
FGB‡
GCTCC 31.5 0 (ref.) 0.001
GTTCA 21.5 2.2 (0.1 to 4.4) 0.039
GCGTA 18.4 4.1 (1.9 to 6.4) 0.001
ACTCA 15.5 1.3 (3.5 to 1.0) 0.270
GCTCA 11.2 0.4 (2.1 to 2.9) 0.780
GCGCA 1.9 7.9 (1.9 to 14.2) 0.010
ATTCA 0.1 15.4 (14.8 to 56.3) 0.355
FGG§
TCCA 40.4 0 (ref.) 0.072
TTCG 30.0 1.0 (2.7 to 0.8) 0.298
ATCA 24.4 1.4 (0.6 to 3.4) 0.171
TCTA 3.6 3.0 (7.0 to 1.1) 0.148
Rare 3.6 (9.2 to 2.4) 0.237
Frequency: haplotype frequency in person-visits. % change: Percentage of change of fibrinogen geometric mean from the reference category. The
italic p values in the reference row come from a likelihood ratio test of the model with all the haplotypes versus the null model (without any
haplotype). *Adjusted for city, gender, age, body mass index, glycosylated hemoglobin HbA1c (%), and smoothed trend. †FGA: rs2070006,
rs10012555, rs2070011, rs2070016, rs2070018, rs6050, rs2070022. ‡FGB: rs1800791, rs1800788, rs2227399, rs6056, rs2227421. §FGG:
rs2066854, rs1800792, rs2066860, rs1049636.
Abbreviations as in Table 2.ssociation Between Mean Plasma Fibrinogen Levels and SNPs rs2070011 in FGAnd rs1800790 in FGB, Stratified by Quartil s of Pla ma IL-6 and CRP Levels*
Table 4 Association Between Mean Plasma Fibrinogen Levels and SNPs rs2070011 in FGAand rs1800790 in FGB, Stratified by Quartiles of Plasma IL-6 and CRP Levels*
Q1 Q2 Q3 Q4
% Change 95% CI % Change 95% CI % Change 95% CI % Change 95% CI p Inter
IL-6
rs1800790
AA 12.3 (4.3 to 20.8) 11.8 (5.1 to 18.9) 10.0 (1.8 to 18.8) 10.1 (0.4 to 20.7) 0.805
GA 3.2 (0.5 to 6.1) 3.9 (1.1 to 6.8) 2.8 (0.2 to 5.9) 3.0 (0.8 to 6.9) 0.960
GG 0.0 (ref.) 0.0 (ref.) 0.0 (ref.) 0.0 (ref.) 0.950
rs2070011
TT 5.3 (1.4 to 9.5) 3.1 (0.7 to 7.0) 5.3 (1.2 to 9.5) 6.4 (1.1 to 12.1) 0.079
CT 0.1 (2.6 to 2.8) 0.3 (2.4 to 3.2) 0.9 (2.1 to 4.0) 1.7 (2.0 to 5.6) 0.046
CC 0.0 (ref.) 0.0 (ref.) 0.0 (ref.) 0.0 (ref.) 0.003
CRP
rs1800790
AA 11.8 (2.4 to 21.9) 9.4 (0.9 to 18.6) 8.1 (1.1 to 15.6) 4.6 (2.8 to 12.6) 0.114
GA 3.0 (0.0 to 6.1) 3.1 (0.3 to 6.0) 3.8 (0.9 to 6.9) 3.3 (0.2 to 7.0) 0.940
GG 0.0 (ref.) 0.0 (ref.) 0.0 (ref.) 0.0 (ref.) 0.287
rs2070011
TT 3.6 (0.6 to 8.0) 5.1 (1.3 to 9.2) 4.7 (0.7 to 8.9) 5.8 (0.9 to 10.9) 0.098
CT 0.2 (2.7 to 3.2) 1.6 (1.3 to 4.5) 0.2 (2.8 to 3.2) 0.1 (3.3 to 3.7) 0.442
CC 0.0 (ref.) 0.0 (ref.) 0.0 (ref.) 0.0 (ref.) 0.058
change: percentage of change of fibrinogen geometric mean from the reference category. p Inter: p value for interaction (from a model with the continuous variable for interleukin [IL]-6 or C-reactive protein
CRP] plasma level and the SNP). The italic p value in reference row comes from the likelihood ratio test between the model containing the interaction term versus the one without it. Q1 contains the values less
han the first quartile, Q2 contains the values between the first and second quartile, and so on. *Adjusted for city, gender, age, body mass index, glycosylated hemoglobin HbA1c (%), and smoothed trend.
Abbreviations as in Table 2.
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ssociated with the intraindividual standard deviation of
ogarithmically transformed fibrinogen levels (coefficient:
0.003, 95% CI: 0.020 to 0.002), and similarly 1 FGB
aplotype, the GCGTA (also associated with fibrinogen
evels) (Table 3), showed a negative association with the
tandard deviation of the logarithmically transformed fi-
rinogen level (coefficient: 0.007, 95% CI: 0.016 to
.001).
iscussion
n the present study, we found that 8 SNPs in the FGA and
GB genes had significant associations with plasma fibrin-
gen levels when evaluated one by one. Furthermore, we
how that specific haplotypes of FGA, FGB, and FGG
ppear to modify the expression of fibrinogen in response to
roinflammatory stimuli such as IL-6, because their effects
n fibrinogen levels became stronger in the presence of high
L-6 levels. We also provide evidence that SNPs and
aplotypes on both FGA and FGB genes may be implicated
n the normally observed intraindividual variability of fibrin-
gen levels.
It is now widely accepted that systemic low-grade inflam-
ation is a key feature in atherogenesis (23), and evidence
ssociation Between Mean Plasma Fibrinogen Levels and FGA,GB, and FGG Haplotyp s, Str tified by Quartiles of Pl sma IL-6 Le
Table 5 Association Between Mean Plasma Fibrinogen Levels aFGB, and FGG Haplotypes, Stratified by Quartiles of Pl
Q1 IL-6 Q2 IL-6
% Change 95% CI % Change 95% CI
FGA†
CTCAATG 0.0 (ref.) 0.0 (ref.)
TTTAACG 1.6 (0.9 to 4.2) 2.3 (0.4 to 4.9)
CTCAATA 1.0 (3.8 to 1.8) 0.6 (3.6 to 2.5)
CTCGATG 3.4 (0.3 to 6.6) 2.7 (0.4 to 5.8)
TCTAGTG 3.6 (0.3 to 7.0) 0.7 (2.5 to 4.0)
Rare 7.7 (1.3 to 17.5) 3.3 (11.1 to 5.1)
FGB‡
GCTCC 0.0 (ref.) 0.0 (ref.)
GTTCA 2.0 (0.6 to 4.6) 1.0 (1.6 to 3.6)
GCGTA 4.5 (1.8 to 7.3) 3.7 (1.1 to 6.5)
ACTCA 0.1 (2.8 to 2.7) 1.0 (3.8 to 1.9)
GCTCA 3.1 (0.1 to 6.3) 1.8 (4.8 to 1.3)
GCGCA 6.4 (0.9 to 14.1) 7.3 (0.7 to 14.5)
ATTCA — —
FGG§
TCCA 0.0 (ref.) 0.0 (ref.)
TTCG 0.8 (3.0 to 1.5) 0.9 (3.1 to 1.3)
ATCA 0.3 (2.1 to 2.8) 0.5 (1.9 to 2.9)
TCTA 0.6 (5.2 to 4.2) 0.0 (5.3 to 5.5)
Rare 5.5 (13.5 to 3.2) 9.7 (16.8 to 2.
change: percentage of change of fibrinogen geometric mean from the reference. p Inter: p value
n reference row comes from the likelihood ratio test between the model containing the interaction
etween the first and second quartile, and so on. *Adjusted for city, gender, age, body mass index,
s2070016, rs2070018, rs6050, rs2070022. ‡FGB: rs1800791, rs1800788, rs2227399, rs6056
Abbreviations as in Tables 2 and 4.uggests that increased plasma levels of inflammatory tiomarkers such as fibrinogen are associated with increased
ardiovascular risk (1,23). It is therefore of importance to
etermine the genetic variables that affect the expression of
brinogen cluster genes and their response to the underlying
roinflammatory stimuli.
enetic determinants of fibrinogen levels. The FGB
hain synthesis is considered the rate-limiting factor for the
roduction of fibrinogen (24), and SNPs on the FGB gene
ave been associated with fibrinogen levels (10,13,25), with
455A (FGB rs18000790) and C148T (FGB rs1800787),
ost widely studied (8,26). The FGB rs18000790 SNP is
robably the most physiologically relevant, because the
enetic variants defined by this SNP have distinct nuclear
rotein-binding properties (26). However, conflicting data
8,27) suggest that complex gene-environment interactions
nd especially the underlying inflammatory status or disease
tate could be important modifiers of this relationship (8).
In this study, we found that 4 SNPs in high mutual LD
n the FGB gene affect fibrinogen levels, with FGB
s18000790 giving the strongest association. Indeed, the
s1800790 SNP is located in the promoter region of the
GB gene (11) and it seems to be a functional polymor-
hism, affecting the expression of FGB and hence the
ynthesis of fibrinogen in experimental models (12,23). On
GA,
IL-6 Levels*
Q3 IL-6 Q4 IL-6
p Inter% Change 95% CI % Change 95% CI
0.0 (ref.) 0.0 (ref.) 0.013
3.2 (0.5 to 6.0) 1.9 (1.5 to 5.3) 0.180
0.7 (3.8 to 2.6) 3.0 (6.7 to 0.8) 0.002
2.2 (1.2 to 5.8) 2.8 (1.5 to 7.3) 0.142
1.0 (2.3 to 4.4) 1.7 (2.7 to 6.2) 0.778
1.9 (9.7 to 6.7) 0.9 (9.9 to 13.0) 0.762
0.0 (ref.) 0.0 (ref.) 0.001
2.4 (0.3 to 5.1) 2.3 (1.1 to 5.8) 0.654
2.6 (0.4 to 5.7) 3.1 (0.5 to 6.9) 0.218
1.2 (4.1 to 1.8) 2.8 (6.2 to 0.8) 0.001
1.0 (4.0 to 2.2) 0.2 (4.3 to 4.0) 0.055
8.9 (1.6 to 16.7) 6.0 (3.1 to 16.0) 0.100
23.3 (8.4 to 65.9) 9.5 (22.7 to 55.0) 0.952
0.0 (ref.) 0.0 (ref.) 0.033
1.2 (3.5 to 1.1) 2.3 (5.0 to 0.5) 0.072
1.4 (1.1 to 3.9) 0.4 (2.6 to 3.5) 0.960
2.7 (7.9 to 2.7) 8.0 (14.0 to 1.5) 0.084
3.8 (11.0 to 4.0) 2.0 (10.1 to 6.9) 0.011
raction (from a model with the continuous variable for IL-6 and the haplotypes). The italic p value
rsus the model without it. Q1 contains the values less than the first quartile, Q2 contains the values
lated hemoglobin HbA1c (%), and smoothed trend. †FGA: rs2070006, rs10012555, rs2070011,
7421. §FGG: rs2066854, rs1800792, rs2066860, rs1049636.vels*
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NPs in this LD group: rs6056 (C4651T), rs4220
C7589A), and rs2227399 (G1683T). Although 1 of these
ould also represent a true relationship, their association
ith fibrinogen levels may well be indirect through their
igh LD with the functional FGB rs18000790 SNP in our
opulation.
We also observed that FGA SNPs rs2070011 (C58T,
ocated in the promoter region) and the correlated
s2070006 (C2027T, located in the promoter region) as well
s rs2070022 (A6892G, located in the untranslated region)
nd the correlated rs2070014 (C1374T located in an in-
ronic area) were each individually associated with fibrino-
en levels, with rs2070011 giving the strongest association.
More importantly, this is the first study demonstrating
hat specific haplotypes on fibrinogen cluster genes regulate
lasma fibrinogen levels in MI survivors. Indeed, we made
he novel observation that 3 haplotypes (1 haplotype in
GA and 2 in FGB) are strong determinants of fibrinogen
evels, not entirely as expected from the SNP analyses,
uggesting that haplotype analyses could provide an addi-
ional future option in evaluating the effects of genetic
ackground on fibrinogen levels.
ther determinants of fibrinogen levels: gene-environ-
ent interactions. It is now widely known that fibrinogen
evels vary across different ethnic groups, as a result of
enetic differences (28), dietary modifiers and the overall
ifestyle (29), with season of the year being an additional
mportant modifier (6). In the present study, we observed
hat apart from some demographic characteristics known to
nfluence plasma fibrinogen levels (e.g., age, gender, and
ody mass index) (30), city of residence was the strongest
redictor. As 99.7% of study participants were Caucasians,
t seems that “city” captures differences beyond ethnicity. In
ur study, city but not ethnicity was a strong determinant of
oth fibrinogen levels and the distribution of the examined
NPs/haplotypes. This finding suggests that factors beyond
thnicity (i.e., cultural and dietary habits, weather varia-
ions, pollution and many others) may affect fibrinogen
evels and genetic differences of European populations are
est described by geographical, linguistic, and cultural
nfluences, which are best described by “city of stay” rather
han “ethnic group,” as previously reported (31).
By performing serial monthly measurements of fibrino-
en levels in the same subjects, we were able: 1) to calculate
ore stable estimates of average individual fibrinogen levels,
hich is an advantage over most previous studies as it
educes measurement random errors; and 2) to examine the
ffect of genotype on the intraindividual variability of
brinogen levels over time. We demonstrate for the first
ime that the intraindividual variability of plasma fibrinogen
s associated with SNPs on the FGB (rs2227421) and
ossibly on FGA (rs2070016) genes, and more importantly
ith haplotypes of both FGA and FGB genes. These novel
ndings imply that the genetic background may be partly sesponsible for the high intraindividual variability of fibrin-
gen levels normally observed in patients with atheroscle-
osis (6,32).
ffects of proinflammatory stimuli on the association
etween SNPs/haplotypes and fibrinogen. Interleukin 6
s the main mediator of acute phase-induced fibrinogen
ynthesis, mainly because it acts on the promoter regions of
he genes encoding all 3 fibrinogen chains (12). The SNPs
n FGB (12) or FGA (27) may modify the response of these
enes to IL-6 in vitro, but at a clinical level, preliminary data
uggested that these SNPs affect plasma fibrinogen levels
nly in subgroups with higher IL-6/CRP levels such as
ealthy smokers (13,14). However, the possible effect of the
aplotypes of FGA, FGB, and FGG on IL-6–induced
brinogen expression has not previously been investigated.
In this study, we were able to show that SNP rs2070011
n FGA modified the association between IL-6 and fibrin-
gen levels. Somewhat surprisingly, there was no clear
ssociation between the rs18000790 SNP in FGB and the
L-6–induced fibrinogen expression.
In addition to the finding that several SNPs in different
reas of the FGA, FGB, and FGG genes affect the response
f these genes to IL-6, we also made the novel observation
hat haplotypes on these genes may have an even stronger
ffect. Indeed, we observed an effect modification of the
L-6 impact on fibrinogen levels, which is related mainly to
haplotype on FGA, 2 haplotypes on FGB, and 2 haplo-
ypes on FGG. These novel findings suggest that the
aplotype-based approach may be more accurate than indi-
idual SNPs to define complex associations between fibrin-
gen genes and variations of its plasma levels in response to
roinflammatory stimuli.
enetics of fibrinogen chains: clinical perspectives. As
lasma fibrinogen is considered to be a risk factor for
therosclerosis (23), it is still unclear whether therapeutic
trategies targeting fibrinogen levels may have the potential
o modify cardiovascular risk. Treatments currently used
gainst atherosclerosis (such as statins or angiotensin-
onverting enzyme inhibitors) improve clinical outcome in
rimary and secondary prevention (33), and they also
ecrease fibrinogen levels (23,34). However, it is unknown
hether plasma fibrinogen is a reliable marker to follow the
esponse to these treatments or whether it could ever be
sed as a therapeutic target itself. As fibrinogen appears to
ave seasonal variability, only serial measurements can
rovide useful information regarding the progression of the
nderlying proinflammatory status. A novel finding of the present
tudy is the suggestion that haplotypes affect the response of
brinogen genes to low-grade inflammation observed in MI
urvivors. These findings imply that multiple genetic vari-
nts in these genes are of importance and that the described
aplotypes could modify the response of fibrinogen levels
o anti-inflammatory treatments, such as statins or
ngiotensin-converting enzyme inhibitors. The present
tudy was not designed to test any pharmacogenomic value
o
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esigned to test such a hypothesis.
tudy limitations. A limitation of the present study is the
bsence of any prospective data examining the effect of these
NPs/haplotypes on long-term clinical outcome. As the
tudy was designed to test the effect of these genotypes on
brinogen levels and variations throughout a period of 6
onths, it was underpowered to detect any impact on
linical events during the follow-up period. In addition, the
orderline, nonsignificant effects of these genotypes on
linical status of these patients at baseline suggests that
urther large-scale prospective clinical studies are required to
emonstrate the effect of these SNPs and haplotypes on
ard clinical end points.
onclusions
n the present study, we demonstrate that genetic back-
round, as defined by specific SNPs and haplotypes of the
GA, FGB, and FGG genes, represents a major determi-
ant of the expression of fibrinogen in post-MI patients,
odifies the response to proinflammatory stimuli, and
ossibly also modifies the intraindividual variability of
brinogen levels. These findings may have important im-
lications on risk stratification of patients with advanced
therosclerosis. Although it is still premature to suggest an
mmediate clinical application of these findings, the results
f the present study may guide the design of genetically
ased approaches for secondary prevention in these patients
n the future.
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